Israel-based Kamada Ltd. says biosimilars are a “key strategic focus in our distribution business,” with plans to launch a portfolio of 11 biosimilar products by 2028.
In a 15 March letter to shareholders, company chief executive officer Amir London notes that the firm was aiming to...






